Floatz Rating
B63/100
Confidence
Indicative
Sponsor
H. Lee Moffitt Cancer Center and Research Institute
Modality
Cell therapy
Development Phase
Phase 2
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
52High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT02652455CT.gov Combining PD-1 Blockade, CD137 Agonism and Adoptive Cell Therapy for Metastatic Melanoma | — | Completed | — | — | — |
NCT01468818CT.gov Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Melanoma | — | Terminated | — | — | — |
NCT01369875CT.gov Modified Tumor Infiltrating Lymphocytes for Metastatic Melanoma | — | Terminated | — | — | — |
NCT01369888CT.gov Use of IL-15 After Chemotherapy and Lymphocyte Transfer in Metastatic Melanoma | — | Terminated | — | — | — |
NCT01118091CT.gov Prospective Randomized Comparative Study of Cell Transfer Therapy Using CD8+-Enriched Short-Term Cultured Anti-Tumor Autologous Lymphocytes Following a Non-Myeloablative Lymphocyte Depleting Chemotherapy Regimen Compared to High-Dose Aldesleukin in M... | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
81High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Skin Cancer
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| TIL (this asset) | H. Lee Moffitt Cancer Center and Research Institute | P2 | B · 63 |
| Prednisone | Dana-Farber Cancer Institute | P4 | BBB |
| Cyclophosphamide | Institute of Oncology Ljubljana | P2 | BB |
| Sirolimus | Dana-Farber Cancer Institute | P4 | BB |
| Nivolumab | 7 Hills Pharma, LLC | P3 | BB |
| Fludarabine | H. Lee Moffitt Cancer Center and Research Institute | P2 | BB |
| Cis-Diamminedichloroplatinum Ii | Toray Industries, Inc | P3 | BB |
| Vinblastine | Memorial Sloan Kettering Cancer Center | P3 | BB |
| Dacarbazine | Memorial Sloan Kettering Cancer Center | P3 | BB |
+41 more in the Skin Cancer cohort
Other indications for TIL
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Cutaneous Melanoma | — | P2 | BBB · 72 |
| Ovarian Cancer | — | P2 | BB · 70 |
| Metastatic Melanoma | — | P2 | BB · 69 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. TIL in Skin Cancer. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/til-skin-cancer
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →